Screener
Halozyme Therapeutics HALO Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 193,345 | 123,278 | 385,536 | 246,604 |
| Operating income | 287,654 | 202,441 | 472,171 | 343,976 |
| Other income (expense) | ||||
| Investment and other income, net | 2,836 | 6,891 | 4,154 | 13,709 |
| Interest expense | (5,588) | (4,394) | (11,096) | (8,919) |
| Income before income tax expense | 284,902 | 204,938 | 465,229 | 348,766 |
| Income tax expense | 54,989 | 39,778 | 85,267 | 65,511 |
| Net income | $229,913 | $165,160 | $379,962 | $283,255 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's other income, net (note 6)?
- Halozyme Therapeutics (HALO) reported other income, net (note 6) of $2.84M in Q2 2026.
- How has Halozyme Therapeutics's other income, net (note 6) changed year-over-year?
- Halozyme Therapeutics's other income, net (note 6) decreased by 58.8% year-over-year, from $6.89M to $2.84M.
- What is the long-term trend for Halozyme Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's other income, net (note 6) has grown at a 110.1% compound annual growth rate (CAGR), from $1.1M to $21.47M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Halozyme Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude